contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


optomed-oyj-new-shares-subscribed-for-in-optomed-plcs-directed-share-issue-have-been-registered-in-the-finnish-trade-register-4

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Optomed operates in the medical technology sector. The company conducts research and development of specialized eye cameras. Development takes place of both hardware and software that are resold under different brands. Operations are held on a global level, with the largest presence in the Nordic market. Customers consist of research institutes and hospitals. The company has its headquarters in Oulu.

Topconin lunastus pörssistä on saatu päätökseen. Kiinnostava vuosi tulossa, kun Topcon määrittelee markkinaa. — Through this MBO, Topcon has formed a strong partnership with KKR Japan Co., Ltd. and JIC Capital, Ltd., who have a deep understanding of our businesses and a strong alignment with our corporate philosophy, to establish a more agile and flexible management structure. This will enable us to accelerate strategic initiatives from a long-term perspective, including bold upfront investments, further strengthen Topcon’s competitiveness and drive the sustainable growth of our corporate value. Following the transition to a private company, the current management team will continue to lead and operate Topcon as before. —                   Topcon Healthcare – 10 Dec 25              Topcon Corporation Completes MBO, Launching the Company’s Next Chapter    Topcon Corporation announces that following the successful completion of a management buyout ("MBO"), under which Topcon's management team has acquired the Company, Topcon's shares were delisted from the stock exchange as of December 2, 2025.         Est. reading time: 1 minute

There’s been a lot of discussion here from different angles about Optomed’s channels and various events. How significant a distribution channel in the United States is the strategic partnership with the IRIS (Intelligent Retinal Imaging Systems) platform? In my opinion, this has been somewhat overlooked, because:   Established customer base: The IRIS platform is already used by over 650 healthcare organizations in the United States. Optomed does not need to search for these customers one by one.   Integrated solution: Optomed’s Aurora AEYE camera is one of the FDA-approved hardware options on this established platform (and the only handheld).   Rapid scaling: The partnership enables rapid access to hundreds of existing customer relationships and facilitates the integration of screening into primary healthcare routines in the United States.   What do others think? I tried to dig up information about IRIS’s customers @usa, but surprisingly found nothing

2024 2025 Change      Q1 3,3 4 +21,21%   Q2 3,5 3,8 +8,57%   Q1+Q2 6,8 7,8 +14,71%   Q3 3,1 4,4 +41,94%   Q4 5,1 4,4 -13,73%   Q3+Q4 8,2 8,8 +7,32%   Q1-Q4 15 16,5 +10,67 %    The table shows that if Q4 revenue is the same as Q3, Optomed’s target of 10% growth will be reached. A positive earnings warning (Posari) requires a revenue of 5.8 million euros. Q2 results were heavily in the negative, as components for cameras were purchased. Now, a share issue was made at an early stage, so that more components for cameras can be ordered again and new permits can be initiated. Wishing a good next year to all Optomed owners.

A long segment has been released by Suther Health, and if you listen to it, Optomed and AI will definitely make a strong breakthrough. The train is moving fast, even though the stock price suggests otherwise:

Leana Wen, a member of Optomed’s board, interviewed CVS Health’s CMO at HLTH USA. The discussion focused on improving access to care, retail healthcare, and rapid diagnostic services — precisely the market that Optomed + AEYE are targeting in the USA. A positive sign: Optomed’s board has direct connections to U.S. healthcare giants (CVS/Aetna), where AI-powered retinal screenings can scale rapidly.                   linkedin.com              #hlthusa | HLTH USA    In a powerful conversation at #HLTHUSA 2025, Leana Wen M.D. M.Sc. sits down with Amy Compton-Phillips, MD, EVP & Chief Medical Officer at CVS Health, to explore one of healthcare’s most persistent challenges: making it easier for people to find,...

Both Aeye and Toku Clair will come to the Lumo camera. Aeye is much easier and faster to get. For Toku, we have to wait for Topcon to get approval first. Lumo Aeye will come first. A small addition : Here, we are first waiting for the Lumo 510k FDA approval to arrive. When that approval comes, it might very well happen that US customers start ordering the Lumo camera as capex. Of course, with the idea that when the Lumo Aeye approval comes, they will adopt it “at the push of a button”.

I agree. Now is the moment when a moat is being built in the United States. All efforts and resources should now be put into that. It has already been stated that the start has been slower than investors and the company itself expected. However, I am of the opinion that if and when Optomed survives alone and as the only one in this segment to the stage where several large chains start scaling the product, a huge competitive advantage and a moat will be created for Optomed. Once this type of device has been deployed, trained, and integrated into systems, it has a clear advantage even if competitors gradually start to emerge. In Finland, procurements go through general tendering, but still, the familiar and reliable device seems to win the tenders, and the scoring often favors the right device. And this tendering problem doesn’t even exist in the private markets of the United States; instead, a proven, familiar product is a relatively easy choice.

Optomed

OPTOMED PLC STOCK EXCHANGE RELEASE 12 December 2025, at 3.45 p.m. EET New shares subscribed for in Optomed Plc's directed share issue have been registered in the Finnish Trade RegisterA total...

OPTOMED PLC&nbsp;STOCK EXCHANGE RELEASE&nbsp;12 December 2025, at 3.45 p.m. EET&nbsp;New shares subscribed for in Optomed Plc's directed share issue have been registered in the Finnish Trade RegisterA total of 1,760,000 new shares subscribed for in Optomed Plc's directed share issue have been registered into the Finnish Trade Register today, on 12 December 2025. After the registration of the new shares, the company will have 21,453,297 shares in total of which 22,042 shares in treasury.The new shares produce the right to dividends and other distribution of assets as well as other shareholder rights as of this registration date.The new shares will be admitted to trading on the official list of Nasdaq Helsinki Ltd on 15 December 2025.&nbsp;Optomed Plc&nbsp;Further enquiriesSakari Knuutti, CFO, Optomed Plc, sakari.knuutti@optomed.com&nbsp;DistributionNasdaq Helsinki LtdPrincipal media www.optomed.com&nbsp;Optomed in Brief Optomed is a Finnish medical technology company and one of the leading providers of handheld fundus cameras. Optomed combines handheld cameras with software and artificial intelligence with the aim to transform the diagnostic process of blinding eye diseases such as rapidly increasing diabetic retinopathy. In its business Optomed focuses on eye screening devices and software solutions related R&amp;D in Finland and sales through different channels in over 60 countries.<div></div>